AstraZeneca's Enhertu recommended for EU approval for early breast cancer
AstraZeneca and Daiichi Sankyo's Enhertu has been recommended for approval in the EU as a treatment for adult patients with resected HER2-positive breast cancer who have residual disease after neoadjuvant treatment. The CHMP based its opinion on the DESTINY-Breast05 trial, which showed Enhertu reduced the risk of invas